Jonathan Aschoff
Stock Analyst at Roth MKM
(0.58)
# 3,812
Out of 4,732 analysts
45
Total ratings
21.15%
Success rate
-32.32%
Average return
Main Sectors:
Stocks Rated by Jonathan Aschoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GTBP GT Biopharma | Initiates: Buy | $11 | $2.39 | +360.25% | 1 | Dec 2, 2024 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $19 → $21 | $8.05 | +160.87% | 2 | Sep 24, 2024 | |
| APVO Aptevo Therapeutics | Maintains: Buy | $555 → $296 | $4.46 | +6,536.77% | 3 | Sep 23, 2024 | |
| BRTX BioRestorative Therapies | Maintains: Buy | $15 → $18 | $1.97 | +813.71% | 4 | Aug 14, 2024 | |
| NUWE Nuwellis | Reiterates: Buy | $17 | $1.21 | +1,304.96% | 2 | Aug 13, 2024 | |
| OTRK Ontrak | Maintains: Buy | $60 → $45 | $1.75 | +2,471.43% | 2 | Aug 9, 2024 | |
| GOVX GeoVax Labs | Initiates: Buy | $20 | $2.22 | +800.90% | 1 | Jul 16, 2024 | |
| CYCC Cyclacel Pharmaceuticals | Maintains: Buy | $21 → $11 | $0.36 | +2,990.76% | 2 | May 3, 2024 | |
| MBRX Moleculin Biotech | Maintains: Buy | $40 | $1.88 | +2,027.66% | 2 | Apr 12, 2024 | |
| CLRB Cellectar Biosciences | Maintains: Buy | $20 → $28 | $0.24 | +11,398.97% | 4 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $40 | $0.82 | +4,778.05% | 2 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $36 | $7.16 | +403.14% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $24 | $0.75 | +3,095.74% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $6.37 | +370.99% | 3 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $200 | $4.79 | +4,075.37% | 1 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $2.04 | +586.27% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $150 → $450 | $0.40 | +112,371.88% | 2 | Feb 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $8 | $0.71 | +1,026.76% | 1 | Jun 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $2.27 | +4,305.29% | 1 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $1.10 | +36,263.64% | 1 | Nov 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $38 | $4.63 | +720.73% | 1 | Mar 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $480 | $0.19 | +250,683.70% | 1 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $96 | $2.08 | +4,515.38% | 3 | Nov 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $6.45 | +101.55% | 1 | Dec 19, 2019 |
GT Biopharma
Dec 2, 2024
Initiates: Buy
Price Target: $11
Current: $2.39
Upside: +360.25%
Zevra Therapeutics
Sep 24, 2024
Maintains: Buy
Price Target: $19 → $21
Current: $8.05
Upside: +160.87%
Aptevo Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $555 → $296
Current: $4.46
Upside: +6,536.77%
BioRestorative Therapies
Aug 14, 2024
Maintains: Buy
Price Target: $15 → $18
Current: $1.97
Upside: +813.71%
Nuwellis
Aug 13, 2024
Reiterates: Buy
Price Target: $17
Current: $1.21
Upside: +1,304.96%
Ontrak
Aug 9, 2024
Maintains: Buy
Price Target: $60 → $45
Current: $1.75
Upside: +2,471.43%
GeoVax Labs
Jul 16, 2024
Initiates: Buy
Price Target: $20
Current: $2.22
Upside: +800.90%
Cyclacel Pharmaceuticals
May 3, 2024
Maintains: Buy
Price Target: $21 → $11
Current: $0.36
Upside: +2,990.76%
Moleculin Biotech
Apr 12, 2024
Maintains: Buy
Price Target: $40
Current: $1.88
Upside: +2,027.66%
Cellectar Biosciences
Mar 28, 2024
Maintains: Buy
Price Target: $20 → $28
Current: $0.24
Upside: +11,398.97%
Mar 27, 2024
Maintains: Buy
Price Target: $12 → $40
Current: $0.82
Upside: +4,778.05%
Mar 7, 2024
Maintains: Buy
Price Target: $25 → $36
Current: $7.16
Upside: +403.14%
Mar 5, 2024
Maintains: Buy
Price Target: $5 → $24
Current: $0.75
Upside: +3,095.74%
Feb 20, 2024
Reiterates: Buy
Price Target: $30
Current: $6.37
Upside: +370.99%
Aug 29, 2023
Reiterates: Buy
Price Target: $200
Current: $4.79
Upside: +4,075.37%
Aug 14, 2023
Reiterates: Buy
Price Target: $14
Current: $2.04
Upside: +586.27%
Feb 14, 2023
Maintains: Buy
Price Target: $150 → $450
Current: $0.40
Upside: +112,371.88%
Jun 15, 2022
Reinstates: Buy
Price Target: $8
Current: $0.71
Upside: +1,026.76%
Feb 25, 2022
Initiates: Buy
Price Target: $100
Current: $2.27
Upside: +4,305.29%
Nov 24, 2021
Initiates: Buy
Price Target: $400
Current: $1.10
Upside: +36,263.64%
Mar 11, 2021
Initiates: Buy
Price Target: $38
Current: $4.63
Upside: +720.73%
Feb 12, 2021
Initiates: Buy
Price Target: $480
Current: $0.19
Upside: +250,683.70%
Nov 17, 2020
Downgrades: Sell
Price Target: $96
Current: $2.08
Upside: +4,515.38%
Dec 19, 2019
Initiates: Buy
Price Target: $13
Current: $6.45
Upside: +101.55%